A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients (NCT05662956) | Clinical Trial Compass
CompletedPhase 2
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
China114 participantsStarted 2022-12-01
Plain-language summary
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG(VA-CAG) as induction regimen in newly diagnosed young patients with acute myeloid leukemia(AML).
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients ≥ 18 years old and ≤ 65 years old
✓. Newly diagnosed as AML patients according to 2016 World Health Organization (WHO) classification;
✓. Patients without receiving prior therapy for AML;
✓. Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3;
✓. Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN
✕. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment; b) An active second cancer that requires treatment within 6 months of study entry.
✕. Female who are pregnant, breast feeding or childbearing potential.